Disrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage.

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• DNA-damaging chemotherapy, like cisplatin, is a cornerstone of cancer treatment but faces challenges from drug resistance and secondary malignancies.
• Translesion synthesis (TLS) is a DNA damage tolerance pathway linked to both chemotherapy resistance and the development of secondary tumors.
• MAD2L2 (Rev7) is a critical protein in TLS, forming essential complexes with TLS polymerases.

Purpose of the Study:

• To identify and characterize small molecules that target MAD2L2 (Rev7) to modulate TLS activity.
• To evaluate the potential of these molecules as therapeutic agents to overcome cisplatin resistance in cancer.

Main Methods:

• In vitro and in vivo binding assays to confirm direct interaction with MAD2L2.
• Assessment of the effect of small molecules on the MAD2L2-Rev1 complex formation.
• Evaluation of cisplatin sensitivity and DNA damage levels in lung cancer cell lines treated with the identified compounds.

Main Results:

• Discovery of two small molecules, c#2 and c#3, that directly bind to MAD2L2.
• Demonstration that these molecules disrupt the MAD2L2-Rev1 complex formation.
• Observation that c#2 and c#3 sensitize lung cancer cells to cisplatin and increase DNA damage.

Conclusions:

• Small molecules c#2 and c#3 show potential as novel inhibitors of translesion synthesis by targeting MAD2L2.
• These compounds represent promising lead candidates for developing new therapeutic strategies to enhance chemotherapy efficacy and combat cancer drug resistance.